ArticlePloS one2025
Nanopore-based targeted next-generation sequencing (tNGS): A versatile technology specialized in detecting low bacterial load clinical specimens.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- A diagnostic performance study of multiplex polymerase chain reaction-based targeted next-generation sequencing for the accurate identification ofFrontiers in cellular and infection microbiology · 2026Article
- The diagnostic value of targeted next-generation sequencing for smear-negative and sputum-scarce pulmonary tuberculosis.American journal of translational research · 2026Article
- Nanopore-targeted sequencing for rapid and accurate diagnosis of tuberculous serous effusions: a prospective evaluation across pleural, peritoneal, and pericardial fluids.Frontiers in medicine · 2026Article
- Diagnostic Utility of Nanopore Sequencing for Tuberculous Serous Effusions.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe 2024 global tuberculosis report indicated that the epidemiological situation of tuberculosis remains concerning. Current tuberculosis detection methods have limitations, highlighting the urgent need to develop more convenient, effective, and widely utilized detection technologies in clinical settings to facilitate early diagnosis and treatment guidance for tuberculosis. Nanopore-based targeted next-generation sequencing (tNGS) offers advantages such as convenience, efficiency, and long-read sequencing, making it a commonly used method for mycobacteria identification.
methodsThis study compared the detection efficiency of tNGS with Xpert MTB/RIF, MTB culture, and AFB smear in sputum samples, BALF samples, and pathological tissue samples to evaluate the clinical applicability of tNGS in diagnosing tuberculosis and low bacterial load tuberculosis, including extrapulmonary and smear-negative cases.
resultsAmong the four detection methods, tNGS demonstrated the highest efficiency, sensitivity, specificity, and AUC values, which are 93.4%, 94.7%, and 0.94, respectively. This method was particularly advantageous for detecting tuberculosis in patients with low bacterial loads, as evidenced by a significantly different positive detection rate in histopathological specimens compared to other methods (P < 0.001). Furthermore, tNGS achieved overall positive detection rates of 93.8% for smear-negative tuberculosis patients and 89.1% for culture-negative tuberculosis patients, both of which were significantly higher than those of other detection methods (P < 0.05). Additionally, tNGS could directly identify bacterial strains and detect mutations associated with drug resistance. In this study, the agreement rate between tNGS strain identification of NTM and the final diagnosis was 94.1%. Among the 21 identified mutation sites associated with rifampicin resistance, one (Pro454His) was located outside RRDR.
conclusionIt is anticipated that tNGS will play a crucial clinical role in the early prevention and control of tuberculosis in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.